PDF(Pubmed)
Abstract：
Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity\'s definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and/or therapeutic interventions in patients with hematological malignancies are described thoroughly.
摘要：
在血液恶性肿瘤中的应用心脏肿瘤学是指针对血癌患者的心血管护理和管理的整合，尤其是白血病,淋巴瘤和多发性骨髓瘤.血液肿瘤治疗相关的心脏毒性处理最常见的心血管并发症的常规化疗，靶向治疗,免疫疗法，嵌合抗原受体T（CAR-T）细胞和肿瘤浸润淋巴细胞疗法，双特异性抗体，和造血干细胞移植。这篇叙述性综述侧重于血液肿瘤治疗相关心脏毒性的定义，风险分层，多模态成像,以及使用心脏生物标志物检测临床和/或亚临床心肌功能障碍和电不稳定性。此外，我们对血液系统恶性肿瘤患者的主要药物和/或治疗性干预措施最常见的心脏毒性特征进行了全面描述.
